BioNexus Gene Lab Corp. (BGLC) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BGLC Revenue Growth
Revenue Breakdown
BGLC's revenue distribution by segment and geography
By Geography
BGLC Revenue Analysis (2016–2024)
As of May 8, 2026, BioNexus Gene Lab Corp. (BGLC) generated trailing twelve-month (TTM) revenue of $9.5 million, reflecting slight decline in growth of -3.3% year-over-year. The most recent quarter (Q3 2025) recorded $2.5 million in revenue, up 12.5% sequentially.
Looking at the longer-term picture, BGLC's 5-year compound annual growth rate (CAGR) stands at +137.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $13.4 million in 2021.
When compared to Healthcare sector peers including QDEL (-3.9% YoY), CLOV (+48.7% YoY), and AEYE (+14.5% YoY), BGLC has underperformed the peer group in terms of revenue growth. Compare BGLC vs QDEL →
BGLC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BGLCCurrent | $9M | -3.3% | +137.1% | -16.5% | |
 QDEL | $2.7B | -3.9% | +10.4% | -33.7% | |
 CLOV | $1.9B | +48.7% | +23.4% | -4.4% | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% |
BGLC Historical Revenue Data (2016–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $9.5M | -2.7% | $1.3M | 13.6% | $-1,573,702 | -16.5% |
| 2023 | $9.8M | -10.6% | $1.3M | 13.6% | $-2,593,588 | -26.5% |
| 2022 | $10.9M | -18.2% | $1.3M | 11.5% | $-291,177 | -2.7% |
| 2021 | $13.4M | +17.3% | $2.2M | 16.4% | $1.1M | 7.9% |
| 2020 | $11.4M | +8872.0% | $1.7M | 15.1% | $1.3M | 11.2% |
| 2019 | $127K | -40.2% | $56K | 44.0% | $-275,705 | -217.2% |
| 2018 | $212K | +97.2% | $29K | 13.5% | $60K | 28.2% |
| 2017 | $108K | - | $79K | 73.2% | $-127,910 | -118.8% |
| 2016 | $0 | - | $0 | - | $-840 | - |
See BGLC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BGLC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BGLC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
Is BGLC's revenue growth accelerating or slowing?
BGLC revenue growth slowed to -3.3%, below the 5-year CAGR of +137.1%. TTM revenue is $9M. The deceleration marks a shift from historical growth rates.
What is BGLC's long-term revenue growth rate?
BioNexus Gene Lab Corp.'s 5-year revenue CAGR of +137.1% reflects the variable expansion pattern. Current YoY growth of -3.3% is near this long-term average.
How is BGLC's revenue distributed by segment?
BGLC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.